{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:58:42Z","timestamp":1791475122742,"version":"4.3.4"},"reference-count":60,"publisher":"American Society of Hematology","issue":"6","license":[{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The use of chimeric antigen receptor (CAR) T-cell therapy is increasing for adult B-cell acute lymphoblastic leukemia (B-ALL), with 3 CD19 CAR T-cell products commercially available. Several key clinical questions related to best practices for CAR T-cell administration in this population exist, and limited prospective randomized trials have been conducted to fill these knowledge gaps. Thus, to help guide clinical practice, we conducted a modified Delphi study to develop and validate consensus recommendations on the administration of commercially available CAR T-cell therapy for adults with B-ALL. Consensus panelists (n = 9) included principal investigators (PIs) from Real World Outcomes Collaborative of CAR T-Cell Therapy in Adult ALL (ROCCA) consortium sites and were selected based on expertise and CAR T-cell center volume. Final panel consensus recommendations were distributed for rating by the remaining PIs from ROCCA consortium sites, which served as the validation group (n = 27). Consensus topics included patient selection, bridging and pre\u2013CAR T-cell leukemia staging, lymphodepletion, and CAR T-cell treatment setting, specific toxicity prevention and management, post\u2013CAR T-cell response assessment and disease monitoring, and the role of consolidation and\/or maintenance therapies after CAR T-cell therapy. Initially, 58 recommendation statements were evaluated for consensus. After 2 panel meetings, a total of 34 statements achieved consensus rating among the expert panel. After rating by the validation group, all but 1 recommendation statement continued to meet consensus, for a total of 33 consensus recommendation statements on the administration of CAR T-cell therapy in adult B-ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2026033559","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:53:36Z","timestamp":1779213216000},"page":"657-668","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study"],"prefix":"10.1182","volume":"148","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-6136","authenticated-orcid":false,"given":"Lori","family":"Muffly","sequence":"first","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-9836","authenticated-orcid":false,"given":"Noelle V.","family":"Frey","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2109-5152","authenticated-orcid":false,"given":"Gregory W.","family":"Roloff","sequence":"additional","affiliation":[{"name":"3Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae A.","family":"Park","sequence":"additional","affiliation":[{"name":"4Division of Hematology Oncology, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[{"name":"5Division of Hematology Oncology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0015-5902","authenticated-orcid":false,"given":"Anjali","family":"Advani","sequence":"additional","affiliation":[{"name":"6Cleveland Clinic Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Bachanova","sequence":"additional","affiliation":[{"name":"7Department of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3424-2425","authenticated-orcid":false,"given":"Ryan D.","family":"Cassaday","sequence":"additional","affiliation":[{"name":"8Division of Hematology and Oncology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3641-6265","authenticated-orcid":false,"given":"Michael","family":"Daunov","sequence":"additional","affiliation":[{"name":"9University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1638-1755","authenticated-orcid":false,"given":"Kaitlyn C.","family":"Dykes","sequence":"additional","affiliation":[{"name":"10Division of Blood and Marrow Transplantation, University of California, San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Irizarry","family":"Gatell","sequence":"additional","affiliation":[{"name":"11Department of Medicine, University of Texas Southwestern, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5407-9875","authenticated-orcid":false,"given":"Michael R.","family":"Grunwald","sequence":"additional","affiliation":[{"name":"12Levine Cancer Institute, Atrium Health, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8249-4128","authenticated-orcid":false,"given":"Talal","family":"Hilal","sequence":"additional","affiliation":[{"name":"13Mayo Clinic, Phoenix, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4304-935X","authenticated-orcid":false,"given":"LaQuisa C.","family":"Hill","sequence":"additional","affiliation":[{"name":"14Baylor College of Medicine, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2411-4742","authenticated-orcid":false,"given":"Omer","family":"Jamy","sequence":"additional","affiliation":[{"name":"15Division of Hematology and Oncology, The University of Alabama at Birmingham, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vamsi K.","family":"Kota","sequence":"additional","affiliation":[{"name":"16Georgia Cancer Center at Augusta University, Augusta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthu Veera","family":"Kumaran","sequence":"additional","affiliation":[{"name":"17University of Arkansas Medical Center, Little Rock, AR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4542-4232","authenticated-orcid":false,"given":"Chenyu","family":"Lin","sequence":"additional","affiliation":[{"name":"18Duke University School of Medicine, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1179-5879","authenticated-orcid":false,"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[{"name":"19Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[{"name":"20Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-8198","authenticated-orcid":false,"given":"Kristen M.","family":"O'Dwyer","sequence":"additional","affiliation":[{"name":"21University of Rochester Medical Center, Rochester, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6368-8557","authenticated-orcid":false,"given":"Caspian","family":"Oliai","sequence":"additional","affiliation":[{"name":"22Division of Hematology\/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8525-9641","authenticated-orcid":false,"given":"Olalekan O.","family":"Oluwole","sequence":"additional","affiliation":[{"name":"23Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9866-462X","authenticated-orcid":false,"given":"Joshua P.","family":"Sasine","sequence":"additional","affiliation":[{"name":"24Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"25Division of Hematology and Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melhem M.","family":"Solh","sequence":"additional","affiliation":[{"name":"26The Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[{"name":"3Section of Hematology\/Oncology, University of Chicago, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie B.","family":"Tsai","sequence":"additional","affiliation":[{"name":"27Loyola University Medical Center, Maywood, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Ulrickson","sequence":"additional","affiliation":[{"name":"28Banner MD Anderson Cancer Center, Gilbert, AZ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumithira","family":"Vasu","sequence":"additional","affiliation":[{"name":"29Department of Internal Medicine, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8644-0968","authenticated-orcid":false,"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[{"name":"30Roswell Park Cancer Institute, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fevzi Firat","family":"Yalniz","sequence":"additional","affiliation":[{"name":"31Division of Hematology and Blood and Marrow Transplantation, University of Kentucky, Lexington, KY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-2041","authenticated-orcid":false,"given":"Stephen A.","family":"Strickland","sequence":"additional","affiliation":[{"name":"32Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5576-0048","authenticated-orcid":false,"given":"Jessica T.","family":"Leonard","sequence":"additional","affiliation":[{"name":"33Division of Hematology Oncology, Oregon Health & Science University, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4328-6021","authenticated-orcid":false,"given":"Bijal D.","family":"Shah","sequence":"additional","affiliation":[{"name":"34Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Aldoss","sequence":"additional","affiliation":[{"name":"35Division of Leukemia, City of Hope, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2026080611221098400_bib1","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results. SEER\u2217Stat Database: Acute Lymphoblastic Leukemia. 2025. Accessed 27 December 2025. https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html."},{"issue":"10506","key":"2026080611221098400_bib2","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0140-6736(25)00864-5","article-title":"Acute lymphocytic leukaemia","volume":"406","author":"Kantarjian","year":"2025","journal-title":"Lancet"},{"issue":"5","key":"2026080611221098400_bib3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"10299","key":"2026080611221098400_bib4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"23","key":"2026080611221098400_bib5","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2406526","article-title":"Obecabtagene autoleucel in adults with B-cell acute lymphoblastic leukemia","volume":"391","author":"Roddie","year":"2024","journal-title":"N Engl J Med"},{"key":"2026080611221098400_bib6","author":"Kymriah (tisagenlecleucel)","year":"2025"},{"key":"2026080611221098400_bib7","author":"Tecartus (brexucabtagene autoleucel)","year":"2025"},{"key":"2026080611221098400_bib8","author":"Aucatzyl (obecabtagene autoleucel)","year":"2024"},{"issue":"8","key":"2026080611221098400_bib9","first-page":"505","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy - a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2026080611221098400_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13643-024-02738-3","article-title":"How Delphi studies in the health sciences find consensus: a scoping review","volume":"14","author":"Schifano","year":"2025","journal-title":"Syst Rev"},{"issue":"4","key":"2026080611221098400_bib11","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2026080611221098400_bib12","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s41375-025-02532-7","article-title":"Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3","volume":"39","author":"Shah","year":"2025","journal-title":"Leukemia"},{"issue":"5","key":"2026080611221098400_bib13","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.24.00321","article-title":"Outcomes after brexucabtagene autoleucel administered as a standard therapy for adults with relapsed\/refractory B-cell ALL","volume":"43","author":"Roloff","year":"2025","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026080611221098400_bib14","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2025-2715","article-title":"Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: a ROCCA analysis [abstract]","volume":"146","author":"Valtis","year":"2025","journal-title":"Blood"},{"issue":"9","key":"2026080611221098400_bib15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.20.03585","article-title":"Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: a Pediatric Real-World Chimeric Antigen Receptor Consortium Report","volume":"40","author":"Schultz","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026080611221098400_bib16","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"2026080611221098400_bib17","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"issue":"10","key":"2026080611221098400_bib18","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1182\/bloodadvances.2025018604","article-title":"CD19 CAR T-cell outcomes in relapsed\/refractory extramedullary B-ALL: a multi-site, retrospective cohort review","volume":"10","author":"Rankin","year":"2026","journal-title":"Blood Adv"},{"issue":"7","key":"2026080611221098400_bib19","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1182\/bloodadvances.2021006035","article-title":"Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy","volume":"6","author":"Holland","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2026080611221098400_bib20","doi-asserted-by":"crossref","first-page":"e711","DOI":"10.1016\/S2352-3026(21)00238-6","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials","volume":"8","author":"Leahy","year":"2021","journal-title":"Lancet Haematol"},{"issue":"16","key":"2026080611221098400_bib21","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1182\/bloodadvances.2024015779","article-title":"Outcomes of brexucabtagene autoleucel in patients with relapsed\/refractory acute lymphoblastic leukemia with CNS involvement","volume":"9","author":"Muhsen","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026080611221098400_bib22","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1158\/1078-0432.CCR-22-2038","article-title":"Favorable activity and safety profile of memory-enriched CD19-targeted chimeric antigen receptor T cell therapy in adults with high-risk relapsed\/refractory ALL","volume":"29","author":"Aldoss","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"suppl 1","key":"2026080611221098400_bib23","article-title":"CD19 CAR T cell therapy is an effective strategy for first CNS relapse in pediatric b ALL [abstract]","volume":"146","author":"DiNofia","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2026080611221098400_bib24","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1182\/bloodadvances.2024014846","article-title":"Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy","volume":"9","author":"Lust","year":"2025","journal-title":"Blood Adv"},{"issue":"22","key":"2026080611221098400_bib25","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Adv"},{"issue":"2","key":"2026080611221098400_bib26","doi-asserted-by":"crossref","first-page":"E38","DOI":"10.1002\/ajh.26787","article-title":"The feasibility of additional CD19-targeted cellular therapy in relapsed\/refractory B-ALL with re-emergence of CD19 antigen after prior CD19-negative relapse","volume":"98","author":"Agrawal","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"2026080611221098400_bib27","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1080\/10428194.2023.2232496","article-title":"Incidence of CD19-negative relapse after CD19-targeted immunotherapy in R\/R BCP acute lymphoblastic leukemia: a review","volume":"64","author":"Locatelli","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2026080611221098400_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)","volume":"105","author":"Yakoub-Agha","year":"2020","journal-title":"Haematologica"},{"issue":"3","key":"2026080611221098400_bib29","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.bbmt.2018.12.068","article-title":"Clinical utilization of chimeric antigen receptor T cells in B cell acute lymphoblastic leukemia: an expert opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation","volume":"25","author":"Kansagra","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"2026080611221098400_bib30","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.jcyt.2022.05.003","article-title":"Leukapheresis guidance and best practices for optimal chimeric antigen receptor T-cell manufacturing","volume":"24","author":"Qayed","year":"2022","journal-title":"Cytotherapy"},{"issue":"12","key":"2026080611221098400_bib31","first-page":"3892","article-title":"Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed\/refractory acute lymphoblastic B-lineage leukemia in children and young adults","volume":"109","author":"Feuchtinger","year":"2024","journal-title":"Haematologica"},{"issue":"23","key":"2026080611221098400_bib32","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1182\/bloodadvances.2024013747","article-title":"Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL","volume":"8","author":"Aldoss","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026080611221098400_bib33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41375-022-01740-9","article-title":"Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia","volume":"37","author":"Ceolin","year":"2023","journal-title":"Leukemia"},{"issue":"2","key":"2026080611221098400_bib34","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/bjh.19551","article-title":"Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T-cell therapy in Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"205","author":"Othman","year":"2024","journal-title":"Br J Haematol"},{"issue":"13","key":"2026080611221098400_bib35","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1182\/bloodadvances.2025015855","article-title":"Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study","volume":"9","author":"Yegya-Raman","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"2026080611221098400_bib36","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41375-022-01546-9","article-title":"CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: a retrospective international study","volume":"36","author":"Jacoby","year":"2022","journal-title":"Leukemia"},{"issue":"16","key":"2026080611221098400_bib37","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1182\/bloodadvances.2024013239","article-title":"Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention","volume":"8","author":"Furqan","year":"2024","journal-title":"Blood Adv"},{"issue":"2","key":"2026080611221098400_bib38","first-page":"131","article-title":"Chimeric antigen receptor T-cell therapy in the outpatient setting: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Oluwole","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2026080611221098400_bib39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"35","key":"2026080611221098400_bib40","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026080611221098400_bib41","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"10","key":"2026080611221098400_bib42","first-page":"955","article-title":"Best practice considerations by The American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"16","key":"2026080611221098400_bib43","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/bloodadvances.2021004234","article-title":"Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia","volume":"5","author":"Muffly","year":"2021","journal-title":"Blood Adv"},{"issue":"1","key":"2026080611221098400_bib44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/2643-3230.BCD-21-0095","article-title":"Next-generation sequencing of minimal residual disease for predicting relapse after tisagenlecleucel in children and young adults with acute lymphoblastic leukemia","volume":"3","author":"Pulsipher","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2026080611221098400_bib45","doi-asserted-by":"crossref","first-page":"1280580","DOI":"10.3389\/fimmu.2023.1280580","article-title":"Impact of disease burden and late loss of B cell aplasia on the risk of relapse after CD19 chimeric antigen receptor T cell (tisagenlecleucel) infusion in pediatric and young adult patients with relapse\/refractory acute lymphoblastic leukemia: role of B-cell monitoring","volume":"14","author":"Molinos-Quintana","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"2026080611221098400_bib46","first-page":"75.e1","article-title":"Practice preferences for consolidative hematopoietic stem cell transplantation following tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia","volume":"30","author":"McNerney","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2026080611221098400_bib47","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1182\/bloodadvances.2022007423","article-title":"Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells","volume":"7","author":"Lamble","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"2026080611221098400_bib48","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"2026080611221098400_bib49","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00262-021-03009-z","article-title":"Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia","volume":"71","author":"Zhang","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"2026080611221098400_bib50","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA Trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"2026080611221098400_bib51","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"14","key":"2026080611221098400_bib52","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/bloodadvances.2023009856","article-title":"Next-generation sequencing-based MRD in adults with ALL undergoing hematopoietic cell transplantation","volume":"7","author":"Liang","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2026080611221098400_bib53","first-page":"788.e1","article-title":"Consolidation with first and second allogeneic transplants in adults with relapsed\/refractory B-ALL following response to CD19CAR T cell therapy","volume":"30","author":"Aldoss","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"25","key":"2026080611221098400_bib54","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"issue":"9967","key":"2026080611221098400_bib55","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"issue":"23","key":"2026080611221098400_bib56","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"issue":"19","key":"2026080611221098400_bib57","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/cncr.30130","article-title":"Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"122","author":"Giebel","year":"2016","journal-title":"Cancer"},{"issue":"7","key":"2026080611221098400_bib58","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/blood.2020005655","article-title":"Concomitant use of a dual Src\/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL","volume":"137","author":"Leonard","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2026080611221098400_bib59","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2026080611221098400_bib60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1182\/blood.2026036233","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/657\/2536528\/blood_bld-2026-033559-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/148\/6\/657\/2536528\/blood_bld-2026-033559-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T15:22:34Z","timestamp":1786029754000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/148\/6\/657\/568519\/Consensus-recommendations-for-CAR-T-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2026033559","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,6]]},"published":{"date-parts":[[2026,8,6]]}}}